Výsledky vyhledávání - "Susan Ramadan"

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor

Autor: Kalle E. Mattila, Siru Mäkelä, Soili Kytölä, Emma Andersson, Pia Vihinen, Susan Ramadan, Tanja Skyttä, Leena Tiainen, Meri-Sisko Vuoristo, Kristiina Tyynelä-Korhonen, Jussi Koivunen, Laura Kohtamäki, Kristiina Aittomäki, Micaela Hernberg

Publikováno v: Acta oncologica (Stockholm, Sweden). 61(10)

Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients.We studied plasma ctDNA as a prognostic biomarker in 19 patients with metastatic melanoma and a detectable tumor mutation (13 BRAF, 5 NRAS, and 1 K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dde8bc1d26f46c50784d8f501709f2db
https://pubmed.ncbi.nlm.nih.gov/36307938

Zobrazit plný text záznamu

Plný text ve formátu HTML

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Autor: Leena Tiainen, Meri-Sisko Vuoristo, Kalle Mattila, Micaela Hernberg, Susan Ramadan, Kristiina Tyynelä-Korhonen, Siru Mäkelä, Laura Kohtamäki, Tanja Skyttä, Pia Vihinen, Jussi Koivunen

Publikováno v: Acta Oncologica. 59:310-314

In the past decades, when dacarbazine-based chemotherapy was the treatment of choice, the median survival of patients with unresectable melanoma was only six to nine months and only 10–15% of the p...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c722566de3d854096947f8eec148d3f4
https://doi.org/10.1080/0284186x.2019.1670862

Zobrazit plný text záznamu

Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab

Autor: Susan Ramadan, Pia Vihinen, Tanja Skyttä, Ilkka Koskivuo, Micaela Hernberg, Meri-Sisko Vuoristo, Pirkko-Liisa Kellokumpu-Lehtinen, Seppo Pyrhönen, Kari Syrjänen, Kristiina Tyynelä-Korhonen

Publikováno v: Melanoma Research. 21:431-437

There are no identified biomarkers that could predict response to antiangiogenic or traditional chemoimmunotherapy in metastatic melanoma. We hypothesized that soluble angiogenic factor receptors might help us to identify patients responsive to treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221dca366c7881d838ea56f046f5db0c
https://doi.org/10.1097/cmr.0b013e32834941d3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání